XML 18 R8.htm IDEA: XBRL DOCUMENT
v3.22.1

Selected Balance Sheet Data | 9 Months Ended
--- | ---
Mar. 31, 2022
Notes to Financial Statements |
Supplemental Balance Sheet Disclosures [Text Block] | Note 3. Selected Balance Sheet Data: Inventories: Inventories consist of (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, | ​ | June 30,
​ |  | 2022 |  | 2021
Raw materials | ​ | $ | 69,263 | ​ | $ | 55,096
Finished goods(1) | ​ |  | 64,742 | ​ |  | 67,108
Inventories, net | ​ | $ | 134,005 | ​ | $ | 122,204
​ (1) Finished goods inventory of $5,722 and $5,456 included within other long-term assets in the respective March 31, 2022 and June 30, 2021, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date. ​ Property and Equipment: Property and equipment consist of (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, | ​ | June 30,
​ |  | 2022 |  | 2021
Land | ​ | $ | 8,603 | ​ | $ | 8,612
Buildings and improvements | ​ |  | 225,378 | ​ |  | 190,661
Machinery and equipment | ​ | ​ | 164,665 | ​ | ​ | 149,410
Construction in progress | ​ |  | 26,508 | ​ |  | 49,073
Property and equipment, cost | ​ |  | 425,154 | ​ |  | 397,756
Accumulated depreciation and amortization | ​ |  | (206,756) | ​ |  | (189,849)
Property and equipment, net | ​ | $ | 218,398 | ​ | $ | 207,907
​ Intangible Assets: Intangible assets consist of (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | June 30,
​ | ​ | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​
Developed technology | ​ | $ | 543,977 | ​ | $ | 552,160
Trade names | ​ |  | 147,311 | ​ |  | 147,640
Customer relationships | ​ |  | 228,943 | ​ |  | 232,493
Patents | ​ |  | 3,249 | ​ |  | 2,926
Other intangibles | ​ |  | 6,313 | ​ |  | 6,316
Definite-lived intangible assets | ​ |  | 929,793 | ​ |  | 941,535
Accumulated amortization | ​ |  | (401,151) | ​ |  | (348,267)
Definite-lived intangibles assets, net | ​ |  | 528,642 | ​ |  | 593,268
In process research and development | ​ |  | 22,700 | ​ |  | 22,700
Total intangible assets, net | ​ | $ | 551,342 | ​ | $ | 615,968
​ Changes to the carrying amount of net intangible assets for the period ended March 31, 2022 consist of (in thousands): ​
​ | ​ | ​ | ​
​ | ​ | ​ | ​
Beginning balance | ​ | $ | 615,968
Acquisitions | ​ |  | —
Other additions | ​ |  | 283
Amortization expense | ​ |  | (55,731)
Currency translation | ​ |  | (615)
Eminence impairment (1) | ​ | ​ | (8,563)
Ending balance | ​ | $ | 551,342
​ The estimated future amortization expense for intangible assets as of March 31, 2022 is as follows (in thousands): ​
​ | ​ | ​ | ​
2022 remainder |  | $ | 18,478
2023 | ​ |  | 71,725
2024 | ​ |  | 68,857
2025 | ​ |  | 65,621
2026 | ​ |  | 61,876
Thereafter | ​ |  | 242,085
Total | ​ | $ | 528,642
​ (1) As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of FY'22. Goodwill: Changes to the carrying amount of goodwill for the period ended March 31, 2022 consist of (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Diagnostics and |  | ​
​ | ​ | Protein Sciences | ​ | Genomics | ​ | Total
Beginning balance | ​ | $ | 392,717 | ​ | $ | 450,350 | ​ | $ | 843,067
Acquisitions(1) | ​ |  | — | ​ |  | (4,407) | ​ |  | (4,407)
Eminence impairment | ​ | ​ | (8,275) | ​ | ​ | — | ​ | ​ | (8,275)
Currency translation | ​ |  | (2,588) | ​ |  | (179) | ​ |  | (2,767)
Ending balance | ​ | $ | 381,854 | ​ | $ | 445,764 | ​ | $ | 827,618
​ (1)As discussed in Note 4, there was an adjustment to the preliminary allocation of the Asuragen acquisition opening balance sheet during the measurement period. We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2021. No indicators of impairment were identified as part of our assessment. During the quarter ended September 30, 2021, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment. As disclosed in Note 1, the Company identified a triggering event and a goodwill impairment charge of $8.3 million in the second quarter of fiscal 2022. No additional triggering events or items beyond the upcoming Eminence liquidation were identified during the quarter ended March 31, 2022. The impairment of the Eminence goodwill is the only impairment of goodwill recorded since the adoption of Financial Accounting Standards Board ("FASB") ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration